Market Data
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
SciSparc Ltd. (NASDAQ:SPRC) jumped 26.8% in premarket trading on Wednesday after the clinical-stage pharmaceutical firm announced it has entered into a binding term sheet to acquire patents and intellectual property tied to advanced endoscopic systems—including the MUSE™ device—from Xylo Technologies Ltd.
The MUSE™ system is a disposable, single-use endoscopic tool used for transoral fundoplication, a minimally invasive procedure for treating gastroesophageal reflux disease (GERD). SciSparc said it intends to pursue global commercialization through exclusive regional distribution agreements, echoing Xylo’s approach in Greater China that generated a $3 million upfront payment.
Under the terms of the agreement, SciSparc will obtain Xylo’s full slate of patents, trademarks, technical know-how, and other intellectual property associated primarily with the MUSE™ platform. In return, SciSparc will issue ordinary shares equal to 19.99% of its outstanding share count to Xylo once the deal closes, with an option to issue pre-funded warrants instead.
The acquisition opens the door for SciSparc to enter the expanding GERD device market—estimated at roughly $2.5 billion in 2024 and expected to reach $3.03 billion by 2030, according to MarkNtel Advisors. The market is projected to grow at a CAGR of 3.24%.
SciSparc plans to replicate Xylo’s licensing and distribution strategy across major global regions, including North America, Europe, and Latin America, as it works to commercialize the device and create new revenue opportunities.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.
U.S. equity futures suggest a mostly unchanged open on Friday, signaling that stocks may carry over Thursday’s muted tone as investors await critical inflation figures. Market participants appear hesitant to make bold moves ahead of the release of consumer price data—a key input to the Federal Reserve’s policy decisions—due shortly after the opening bell. The […]
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
